News originally posted at Business Insider

Enlivex Therapeutics Ltd., a clinical stage immunotherapy company, announced today the closing of an $8 million equity financing round at a valuation of approximately $50 Million pre-closing.

Korea Investment Partners (KIP) has invested USD 6 million in the financing round, and Hadasit Bio Holdingings Ltd. (HBL) (TASE:HDST) has co-invested USD 2 million.

Following the closing, KIP has appointed two new members to Enlivex’s Board of Directors.

The financing is expected to fund the commencement of Phase III clinical trials of Enlivex’s lead compound, Allocetra™. Allocetra™ is indicated for the prevention of Graft Vs Host Disease (GVHD) post bone-marrow transplantation. In addition, Enlivex will continue pre-clinical and clinical development for other immunotherapy indications.

Shai Novik, Chairman of Enlivex, commented: “We are…”

See the entire article.